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Abstract 
Aims: Although cardiac amyloidosis (CA) is characterized by significant left atrial (LA) dilatation, 
the characteristics of LA function remain to be fully investigated.  
Methods and Results: We assessed LA function by speckle-tracking echocardiography in 124 
patients with CA and sinus rhythm: 68 with light chain (AL), 29 with mutant (ATTRm), 27 with 
wildtype (ATTRwt) transthyretin amyloidosis. Conventional and strain-derived parameters, 
including LA peak longitudinal strain (LS) and strain rate (peak LSR: reservoir function; early LSR: 
conduit function; late LSR: active function), were assessed compared between CA patients and 20 
healthy controls of similar age and gender. 
Results: All LA function phases, including LA longitudinal strain, peak LSR, early and late LSR 
were significantly impaired in CA compared  to healthy controls after adjusting for LA size, LV 
ejection fraction and LV filling pressures (E/E’) (all p < 0.05).  
Peak LA LS was moderately correlated with LV global LS (R=-0.60, p<0.001); late LSR was 
correlated with A wave at the level of LV inflow (R=-0.69, p<0.001). Among the different CA 
subtypes, peak LS and LA active emptying fraction were worse in ATTRwt than AL and ATTRm 
[p<0.05 after adjustment for age, sex, body mass index, systolic blood pressure, heart rate, LA 
volume index, severity of mitral regurgitation, left ejection fraction and left ventricular end-diastolic 
pressure (E/E’)]. 
Conclusions: In CA, LA function was severely impaired and highly correlated with LV 
deformation. Differences in LA function between amyloid subtypes suggest that amyloid etiology 
plays a role in the pathophysiology of cardiac dysfunction in CA.  
                                                                                                                    (250/250)             
Keywords: amyloid, cardiomyopathy, left atrial function, echocardiography, 2-dimensional speckle 
tracking. 
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Introduction 
Cardiac amyloidosis (CA) is caused by intramyocardial amyloid infiltration1, 2 due to one of 
several etiologies, including: immunoglobulin light chains (AL) amyloidosis, in which a clonal 
plasma cell dyscrasia produces the immunoglobulin light chains responsible of the amyloid 
deposits; hereditary transthyretin (TTR) amyloidosis (ATTRm), which can be caused by over 100 
point mutations in the TTR gene, and  non-hereditary (i.e. wild-type) TTR amyloidosis (ATTRwt), 
which mainly affects the heart of elderly men.1, 2  
Amyloid can virtually infiltrate all cardiac chambers. Most studies have focused on the 
consequences of amyloid infiltration throughout the left ventricle (LV), which include a progressive 
increase of wall thickness and LV stiffness.1, 3, 4 Left atrial (LA) or bi-atrial enlargement is a 
common finding in CA.5 However, LA enlargement is an anatomical measurement and does not 
necessarily reflect its function. Although LA size has been reported to be a poor prognostic 
indicator in CA patients, 6 a comprehensive and quantitative characterization of LA function and its 
implications in CA is lacking.  
         Two-dimensional (2D) myocardial deformation imaging is a robust and sensitive 
echocardiographic technique for the quantitative assessment of LA function 7 and has proven to 
play an adjunctive role in the diagnosis and prognostic stratification of CA.  
We used 2D derived speckle-tracking imaging to characterize LA function in CA and to 
determine whether the progressive reduction of LA contribution to LV filling is secondary to the 
restrictive LV physiology, intrinsic LA dysfunction due to direct amyloid infiltration, or a 
combination of both. We also compared the profiles of the different CA subtypes to investigate 
whether any observed differences in LA structure and function might account for the reported 
markedly different prognoses, (median survival ~ 6 months in untreated AL CA vs. 6 years in 
ATTRwt.8  
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Methods 
Setting and study design 
We conducted a multicentre retrospective study of patients with etiologically defined CA 
from two large international amyloidosis centers, the Brigham and Women’s Hospital (BWH, 
Boston) and the S.Orsola-Malpighi Hospital (Bologna). All consecutive patients diagnosed with CA 
at the Brigham and Women’s Hospital (Boston) from 2006 to 2012 (n=110), or at the S.Orsola-
Malpighi Hospital (Bologna) from 2009 to 2012 (n=62) as previously reported4 were reviewed. 
Patients were included in the present analysis if sinus rhythm was documented at the time of their 
presentation at either center. We compared their baseline clinical profiles and echocardiographic 
parameters, with particular focus on LA structure and function, with those of 20 healthy controls 
retrospectively identified from the medical records of the BWH. Furthermore, we compared the LA 
indices among the different etiologic subtypes. At the Bologna center, all patients provided 
informed consent for anonymous publication of scientific data. At the Boston center, the collection 
of anonymized medical records was approved by the institutional review board.   
 
Definitions of cardiac amyloidosis, etiological subtype and control 
Definition of systemic amyloidosis, including etiological diagnosis of AL, ATTRm and 
ATTRwt amyloidosis, and CA have been previously reported.4 Briefly, diagnosis of systemic 
amyloidosis was defined by histological documentation of Congo-red staining and apple-green 
birefringence under cross-polarized light in at least one involved organ.9 
Cardiac involvement was defined as an echocardiographic end-diastolic LV wall thickness 
greater than 1.2 cm (in the absence of any other plausible causes of LV hypertrophy).1, 2, 10 Other 
echocardiographic signs suggesting CA (in addition to increased LV wall thickness) included: 
granular sparkling appearance of the myocardium, increased thickness of atrioventricular valves, 
right ventricular free wall, or interatrial septum, and pericardial effusion. In selected cases with 
equivocal echocardiographic findings who did not undergo an endomyocardial biopsy, cardiac 
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magnetic resonance and nuclear imaging, including 99mTc-labeled 3,3-diphosphono-1,2-
propanodicarboxylic acid (DPD, available in Europe) and 99mTc-labeled pyrophosphate (PYP, 
available in the U.S.A.) were performed to confirm the presence and nature of intramyocardial 
amyloid deposits.11, 12 
 Distinction between AL and TTR-related amyloidosis was based on genotyping and/or 
immunohistochemistry or mass spectrometry.1, 9 AL was defined by the presence of monoclonal 
plasma cell dyscrasia with serum electrophoresis, serum or urine immunofixation, and abnormal 
serum free light chain assay, in the absence of any TTR mutation at DNA analysis.13, 14 Diagnosis of 
familial ATTRm was defined by a documented TTR mutation with DNA analysis following 
procedures described elsewhere.15 ATTRwt was defined by positive immunohistochemistry for TTR 
in the absence of any TTR mutation at DNA analysis.16 In equivocal cases, biopsy specimens 
underwent proteomics evaluation.17 
A group of 20 healthy controls was retrospectively identified from the medical records of 
the BWH. The search strategy targeted patients aged 55 years or older, who had an echocardiogram, 
and no International Classification of Diseases 9th Revision (ICD-9) code in their record for any of 
the following conditions: hypertension, ischemic heart disease, cardiac arrhythmia, dyslipidemia, 
chronic obstructive lung disease, diabetes mellitus, cerebrovascular disease, arterial vascular 
disease, and cancer. This group was further selected to have normal LVEF, no LV regional motion 
abnormalities, normally sized cardiac chambers, no significant valvular disease, and suitable 
echocardiogram image quality. Controls had a similar age and gender distribution to the CA group.  
 
Echocardiographic Methods  
Echocardiograms were performed at both centers using commercially available ultrasound 
systems (iE33, Philips Medical Systems and Vivid 7, GE Medical Systems, Milwaukee, WI). 
Images were acquired in DICOM format using a frame rate of 50-70 fps. Analysis of the 
echocardiographic images (both conventional and speckle tracking-derived measurements) was 
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conducted at the cardiac imaging core laboratory of the Brigham and Women’s Hospital, blinded to 
clinical information, as previously described.4 A minimum of 3 cardiac cycles were recorded for 
each image and measurement were averaged accordingly. 
Standard echocardiographic and Doppler parameters were analyzed using an offline analysis 
workstation. All measurements were made in accordance with the recommendations of the 
American Society of Echocardiography (ASE).18-20 
Because dedicated software for LA strain analysis has not yet been released, we used 2D 
speckle tracking vendor-independent software with algorithms designed for LV analysis (TomTec 
Imaging Systems, Germany) to study LA deformation.  
If more than 2 segments in LA and LV could not be tracked or there was a lack of a full 
cardiac cycle, missing views, non-DICOM images, significant foreshortening of the cavities, or 
pulmonary vein drop out for the images focused on the LA, the measurements were considered 
unreliable and the patient was excluded from the analysis. Speckles were tracked frame by frame 
throughout the LA and LV myocardium over the course of one cardiac cycle; basal, mid, and apical 
regions of interest were then created. Semi-quantitative segment tracking was carefully inspected. 
The LA and LV endocardial borders were traced at the end-diastolic frame. End-diastole was 
defined by the QRS complex or as the frame after mitral valve closure.  
For LV deformation, global longitudinal strain (GLS) was calculated as the average LV 
longitudinal strain across the 12 segments obtained using apical 4- and 2-chamber views as 
previously described.4  
For LA speckle tracking analysis, LA phasic function was measured using volumes and 
strain indices calculated as the average of the 12 segments obtained using apical 4- and 2-chamber 
views. LA time-volume curves were generated by calculating LA volume at each phase of the 
cardiac cycle (LA maximal, LA pre-A, and LA minimum volumes) using the Simpson method. 
From these LA volumes, LA phasic function was estimated as (Figure 1A):  
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- LA emptying fraction (reservoir function)=([LA maximum volume−LA minimal 
volume]/LA maximum volume)×100  
- LA passive emptying fraction (conduit function)=([LA maximum volume−LA pre-A 
volume]/LA maximum volume)×100  
- LA active emptying fraction (pump function)=([LA pre-A volume−LA minimal 
volume]/LA pre-A volume]×100 
From the LA strain analysis, LA reservoir function was estimated using peak strain during 
ventricular systole (systolic or peak LA strain), which represents the LA filling during LV systole. 
Because the LA expands during ventricular systole, peak LA strain is a positive strain value. LA 
conduit function was estimated using the early peak strain rate (SR) during LV diastole (LA passive 
strain rate), while LA pump function was estimated using late peak SR during LV diastole (LA 
active SR). (Figure 1A and 1B).21-23  
All measurements were performed by a single investigator blinded to clinical status. 
Intraobserver variability for LA LS and LSR was assessed by measuring three times in the whole 
sample. The coefficients of variation for LA measures were as follows: LA LS 10.9%, peak LSR 
13.2%, early LSR 13.6%, and late LSR 23.5%.  
 
Follow-up 
In both centres, follow-up visits were planned for every 6 months (or more frequently if 
clinically appropriate). Follow-up was closed in 2013, May; for patients who had not attended a 
visit in the last 6 months, vital status was ascertained by telephone and/or by contacting referring 
physicians. However, of 124 patients, 11 patients had missing information on death and were 
excluded from the analysis.  
During a median follow-up of 24.4 [17-33] months, we observed 34 (30%) deaths (27 
among AL patients, 3 among ATTRm patients, and 4 among ATTRwt patients), with a death rate of 
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1.8/100 person years among AL patients, 0.3/100 person years among ATTRm patients, and 
0.6/100 person years among ATTRwt patients (Supplementary Figure 1). 
 
Statistical Analysis 
Summary statistics were expressed as mean±SD, median (interquartile range) or numbers 
(percentages). Comparisons between CA patients and healthy controls were performed using 
Student’s t test for continuous normally distributed variables, Mann–Whitney test for continuous 
non-normally distributed variables, and Fisher exact test for categorical variables. Pearson’s 
correlation coefficient was used to evaluate the correlation between LA function and age, systolic 
blood pressure, heart rate, LV function, LV structure, and LA size.  
In a subgroup analysis, we divided the CA group into severely enlarged (left atrial volume 
index (LAVI) ≥48 ml/m2) and not severely enlarged LA (LAVI<48ml/m2) according to ASE 
guidelines.18, 19 
            When comparing the profile of the three different CA subtypes, continuous variables were 
tested using one-way analysis of variance or Kruskal-Wallis test in case of normally and not 
normally distributed variables, respectively. Additional comparisons between CA subtypes were 
performed using multivariable linear regression to adjust for variables that may influence LA size or 
function, including age, sex, BMI, systolic blood pressure, heart rate, LA volume index to body 
surface area (BSA), severity of mitral regurgitation, LV ejection fraction and LV end-diastolic 
pressure as measured by mitral inflow to mitral relaxation velocity ratio (E/E’).  
          Analyses were conducted using STATA 13 SE (Stata Corporation, College Station, TX). All 
tests were two-sided and a p-value < 0.05 was considered statistically significant.  
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Results 
Study population and baseline characteristics 
Of the 172 patients diagnosed with CA during the study period, 124 (72%) were in sinus 
rhythm at the time of echocardiography and were included in the present analysis (AL, n=68; 
ATTRm, n=29; ATTRwt, n=27). Among patients with ATTRm, TTR variants were distributed as 
follows: Ile68Leu (n=8), Glu89Gln (n=6), Val122Ile (n=4), Thr60Ala (n=4), Thr49Ala (n=2), 
Val30Met (n=1), Arg34Thr (n=1), Glu54Gln (n=1), Gly47Ala (n=1), Thr59Lys (n=1). 
Compared to patients in sinus rhythm, those without were older, more frequently male, with 
a higher prevalence of ATTRm, more advanced heart failure symptoms and more frequent history 
of heart failure hospitalizations as well as beta blocker and diuretic usage (Supplementary Table 
1).  
Table 1 and Table 2 summarize the demographic, clinical and echocardiographic findings 
in the overall CA population (n=124) compared to healthy controls (n=20) and according to the 
specific etiology of CA, respectively. As expected, all echocardiographic measures, including 
interventricular septum, posterior wall, LV end-diastolic volume, ejection fraction and GLS, E/E’, 
as well as LA volume and width, were abnormal in CA patients (Table 1).  
As anticipated, ATTRwt patients were more likely to be elderly males with longer disease 
duration and a higher degree of both morphological and functional echocardiographic impairment, 
including thicker cardiac walls and worse contractility and longitudinal systolic function (Table 2). 
No statistical differences were observed among the 3 etiologies of CA in NT-proBNP levels or 
glomerular filtration rate.  
 
LA structure and function 
Table 3 summarizes the LA phasic function in (A) CA patients vs. healthy controls and (B) 
according to the specific etiology of CA. Compared to healthy controls, CA patients showed worse 
strain-derived LA reservoir, conduit and active function, including peak LS, peak LSR, early LSR 
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and late LSR, even after adjusting for LA volume indexed to body surface area (LAVI), (Table 
3A).  
The unadjusted comparison between AL, ATTRm and ATTRwt (Table 3B) did not show 
any significant differences in LA phasic (reservoir, conduit and active) functions, although ATTRwt 
showed lower peak LS, peak LSR, early LSR, late LSR and active emptying fraction. LA peak LS 
was frequently impaired in all etiologies, being abnormal (i.e. under -1.96 SD from the mean value 
in the control group) in 81%, 74% and 91% of AL, ATTRm and ATTRwt patients, respectively. 
ATTRwt etiology was associated with significantly lower LA peak LS and LA active emptying 
fraction when adjusting for age, gender, body mass index, systolic blood pressure, heart rate, LAVI, 
severity of mitral regurgitation, LV ejection fraction and LV end-diastolic pressure (E/E’) (Table 
3B).  
When stratifying CA patients by the severity of LA enlargement (LAVI cut-
off=48ml/m2)18,19, those with LAVI≥48ml/m2 showed worse LA reservoir and active function 
compared to both healthy controls and CA patients with LAVI<48ml/m2 (Figure 2). However, 
when considering LA conduit function, only LSR was worse in CA patients with severely dilated 
LA.  
 
Correlation between LA strain measures and other clinical and echocardiographic findings 
Overall, in CA patients, LA reservoir, conduit and pump functions were correlated with LV 
mass index, parameters of LV function and LA size (Table 4). LV GLS was correlated with LA 
peak LS (Pearson R=-0.60, p<0.0001), peak LSR (R=-0.54, p<0.0001) and late LSR (R=-0.54, 
p<0.0001); a weak correlation between LV GLS and early LSR (R=0.30, p=0.0020) was also 
observed. Notably, Late LSR also showed a strong negative correlation with A wave measured at 
the mitral inflow level (R=-0.69, p<0.0001). 
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Discussion 
This is the first study that provides a systematic assessment of LA function in a large cohort 
of consecutive patients with the three main etiologies of CA.  
We showed that all 2D speckle-tracking derived LA phasic functions were severely 
impaired in CA and highly correlated with LV deformation. LA reservoir function (peak LS) was 
correlated with LVMI, LV GLS, LV ejection fraction, and diastolic measures and LA dimensions. 
In our cohort, ATTRwt seemed to show the worst profile of LA function. These findings support 
speckle-tracking imaging as a sensitive tool to assess LA function in CA and aim to gain further 
insights into the pathophysiology of LA dysfunction in CA.  
Echocardiographically, LA function has been classically studied by means of LA size, 
phasic volumes, and emptying fraction. In particular, LA dimensions and volumes have been widely 
correlated with cardiovascular morbidity and mortality in various pathological conditions.24, 25 
However, LA phasic volumes can be influenced by loading conditions. TDI-derived myocardial 
velocities provide a less load dependant measure of both LV systolic and diastolic function, where 
a’ represents a marker of atrial function. However, TDI measures are angle-dependent and can be 
influenced by translation and tethering.  On the other hand, strain analysis using speckle tracking is 
a direct measurement of intrinsic LA myocardial deformation, relatively independent of loading 
conditions and geometric assumptions26, 27 and with high feasibility and reproducibility.28 
Previous studies have addressed LA function in CA. Modesto et al showed an impaired 
reservoir function in AL patients (peak LS and peak LSR) by colour Doppler myocardial imaging. 
29 De Gregorio et al showed an impairment in LA reservoir and pump function among patients with 
TTR-CA and HCM (n=16 in each group), as compared to normal controls, but mainly in the former 
group, irrespective of LA volume and LV ejection fraction.30 Our results are consistent with such 
findings. Indeed, we showed that LA conduit and active functions were impaired in all the three 
etiologies of CA (Table 3). However, when considering LA conduit function, while early LSR was 
lower in CA than in controls, LA passive emptying fraction did not differ significantly between CA 
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and controls, suggesting that LA volume changes (conduit function) may be a compensatory 
mechanism when LA reservoir and pump function are impaired. 
Worse LA strain was correlated with a greater impairment of LV systolic and diastolic 
function. This association suggests that amyloid infiltration progressively impairs both LV and LA 
function in parallel. A, LV longitudinal systolic dysfunction, which is typical of myocardial 
amyloid infiltration, may contribute to LA dysfunction because of the influence of downward 
motion of the mitral plane during ventricular systole, leading to reduced systolic expansion of the 
LA.31  
Taken together, our findings support the combination of restrictive LV physiology with 
raised filling pressures (due to intramyocardial amyloid infiltration) and intrinsic LA failure (due to 
direct amyloid infiltration) as the main determinant of LA enlargement and dysfunction in CA21,32 
Indeed, in our population LA strain was highly correlated with LV GLS. In addition, a direct injury 
of LA walls was suggested by the impairment in all LA function phases (independently of LA size), 
including late LSR (which reflects the intrinsic active LA contraction), that were significantly worse 
in CA than similar age and gender matched healthy controls, even after adjustment for LA volume, 
LV systolic and diastolic function. This finding is supported by previous magnetic resonance 
studies showing a relatively high prevalence of late gadolinium enhancement throughout the LA 
walls of CA patients.32 The relatively low prevalence of significant mitral regurgitation in our 
population suggests that mitral valve disease is not a major factor responsible for LA dysfunction in 
our patients.33  
Patients with ATTRwt seemed to show worse LA function parameters compared to the other 
etiologies of CA, especially AL. It is well known that ATTRwt is a disease characterized by slowly 
progressive amyloid deposition.1 Indeed patients with ATTRwt had longer disease duration (median 
24.4 months) compared to those with AL (8.6 months) or ATTRm (15.4 months). We therefore 
anticipated more morphological and functional impairment of both LA and LV in ATTRwt. 
However, as already reported by our and other groups, the severity of heart failure and survival are 
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much worse in AL amyloidosis compared to ATTRwt 2, 8 with a median survival of approximately 6 
months in untreated AL amyloidosis with heart failure and 6 years in ATTRwt.2 It was out of the 
scope of the present study to address the natural history and prognostic role of LA dysfunction 
among the different etiologies of CA. However, it is likely that in ATTRwt, given the more chronic 
nature of amyloid deposition, compensatory mechanisms occur to counteract the effects of 
myocardial amyloid infiltration, including LV hypertrophy. On the contrary, in AL, an acute toxic 
effect exerted directly on cardiac myocytes34 or a more rapid rate of amyloid infiltration may lead to 
LA dysfunction even in the absence of significant LA dilatation. Furthermore, other non-myocardial 
factors (including multi-organ involvement, autonomic dysfunction, or a direct microvascular 
infiltration) may play a critical role in the poor prognosis of AL amyloid subtype.35  
 
Clinical Implications 
Although often ignored, the assessment of left atrial function in CA should be performed 
routinely in the clinical practice. Indeed, even in the absence of supraventricular arrhythmias such 
as atrial fibrillation or atrial flutter, patients with CA are predisposed to developing mural thrombi. 
In one large necropsy series, 26% of patients with cardiac amyloidosis were found to have intra-
cardiac thrombi.36 In another series, 42/156 (27%) CA patients undergoing transesophageal 
echocardiography were diagnosed with intracardiac thrombi, with a higher frequency in AL vs. 
other etiologies (35% vs. 18%), despite older age and a higher prevalence of atrial fibrillation in the 
non-AL group.37, 38 This phenomenon, which is generally due to atrial standstill derived from 
markedly increased LV diastolic pressures and intrinsic LA dysfunction, raises concerns regarding 
the appropriate use of anticoagulation therapy in CA. In this context, the study of LA function by 
means of standard and speckle tracking deformation imaging could represent a useful clinical tool 
to identify CA patients with higher thromboembolic risk in whom anticoagulation may be indicated 
beyond the standard risk scores (including CHADSVASC and CHA2DS2VASC).“ 
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Limitations 
Several limitations should be noted. This study included a large series of patients with the 
three main etiologies of CA. However, the absolute number of patients within each etiology is 
relatively small. To provide reference values of LA strain and strain rate, we selected healthy 
individuals as controls. However, we acknowledge that the number of age-matched healthy controls 
was small and we did not compare our findings with those of patients with similar degrees of LA 
enragement due to other cardiac diseases such as dilated or hypertrophy cardiomyopathy. This may 
limit our ability to distinguish between the effect of direct amyloid infiltration and more passive 
effects secondary to LV dysfunction in determining LA dysfunction. The overall advanced stage of 
the disease presented by CA patients in the present study precludes any possible insights into the 
earlier stages of CA, which will need a dedicated study. Finally, this study did not include any 
correlation with clinical outcomes, limiting the power to assess the predictive value of LA strain 
measurements. 
 
Conclusions 
In patients with CA, each phase of LA function assessed by 2D speckle-tracking 
echocardiography was severely impaired and highly correlated to left ventricular deformation but 
independent of LA size. The impairment of both passive and active LA function suggests a 
combination of both LV and intrinsic LA failure in the pathophysiology of LA dysfunction. 
Despite the known different clinical courses, LA function was more impaired in ATTRwt 
compared to AL amyloidosis. This might indicate that in AL, given the more rapid progression of 
amyloid infiltration and the direct toxic effect exerted by circulating light chains on cardiac 
myocytes, cardiac dysfunction and heart failure may precede the overt morphological and 
functional left ventricular and atrial impairment, which seem to be more pronounced in ATTRwt 
due to a longer course of amyloid deposition.  
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Figure legends 
 
Figure 1A. Representative examples of left atrial (LA) measurements in a healthy control case.   
LA maximal volume (Max), LA pre emptying volume (Pre), LA minimal volume (Min), 
longitudinal strain (LS), and longitudinal strain rate (LSR). 
 
Figure 1B. Representative examples of left atrial (LA) measurements in a patient with advanced 
cardiac amyloidosis with enlarged LA and lower LA peak LS, peak LSR, early LSR and late LSR. 
 
Figure 2. Comparison of left atrial (LA) function (reservoir, conduit and pump functions) in healthy 
controls and cardiac amyloidosis (CA) patients with LAvolume index (LAVI)<48 ml/m2 and CA 
patients with LAVI>48ml/m2, bases on t test comparison. 
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Table 1. Demographic, clinical and echocardiographic characteristics in healthy controls vs. cardiac 
amyloidosis (CA). 
 
Healthy Controls CA 
 
 
n=20 n=124 P value 
Age, yrs 66.5 ± 5.0 64.1 ± 11.9 0.37 
Male sex, n (%) 13 (65.0%) 86 (69.4) 0.70 
Etiology, n (%) 
  
... 
     AL ... 68 (54.8) 
      ATTRm ... 29 (23.4) 
      ATTRwt ... 27 (21.8) 
 Systolic blood pressure,  mmHg 125 ± 15 119 ± 20 0.27 
Diastolic blood pressure, mmHg 72 ± 13 72 ± 10 0.91 
Heart rate, bpm 74 ± 19 76 ± 14 0.55 
BMI, kg/m2 24.2 ± 3.8 25.2 ± 4.3 0.33 
Echocardiography    
    LVEDD, cm 4.4 ± 0.6 4.3 ± 0.6 0.44 
    IVS, cm 1.0 ± 0.2 1.6 ± 0.3 <0.001 
    PW, cm 0.9 ± 0.1 1.5 ± 0.2 <0.001 
    LVEDV/BSA, ml/m2 53.3 ± 11.8 45.7 ± 11.5 0.017 
    LVESV/BSA, ml/m2 22.3 ± 8.2 20.4 ± 7.9 0.38 
    LV mass index (BSA), g/m2 81.9 ± 19.0 147.1 ± 42.1 <0.001 
    LV ejection fraction, % 59.4 ± 3.5 56.0 ± 11.0 0.19 
    GLS, % -19.9 ± 2.5 -13.0 ± 4.2 <0.001 
    E wave, m/s    
    A wave,  m/s 0.7 ± 0.2 0.6 ± 0.3 0.023 
    EA ratio 1.0 ± 0.2 1.8 ± 1.0 <0.001 
    E’ (lateral) , cm/s 9.5 ± 2.1 6.1 ± 2.2 <0.001 
    E/E’ (lateral) 7.4 ± 2.0 15.1 ± 7.6 <0.001 
    A’ (lateral), cm/s 10.66 ± 2.63 5.91 ± 2.98 <0.001 
    S’ (lateral), cm/s 8.39 ± 1.71 5.72 ± 2.15 <0.001 
LA structure    
    LA volume (BSA) ml/ m2 20.8 ± 4.2 37.7 ± 13.0 <0.001 
    LA width, cm 3.4 ± 0.4 4.4 ± 0.6 <0.001 
 
Abbreviations: NYHA, New York Heart Association; eGFR, glomerular filtration rate; BMI, body-
mass index, LVEDD, left ventricular end-diastolic dimension, IVS, interventricular septum; PW,  
posterior wall; LVEDV, left ventricular end-diastolic volume, LVESV, left ventricular end-systolic 
volume, BSA, body surface area; GLS, global longitudinal strain; E/A, early to late mitral inflow 
velocity ratio; E’, lateral mitral early relaxation velocity; A’, lateral mitral late relaxation velocity; 
S’, lateral mitral systolic velocity; E/E’, mitral inflow to mitral relaxation velocity ratio. 
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Table 2. Demographic, clinical and echocardiographic characteristics according to the etiological 
subtype of cardiac amyloidosis. 
 Total n=124 
AL 
n=68 
ATTRm 
n=29  
ATTRwt 
n=27  
P value  
(AL vs. 
ATTRm) 
P-value 
(AL vs. 
ATTRwt) 
Age, years 62.1 ± 10.7 59.1 ± 13.1 74.4 ± 6.5* 0.23 <0.001 
Male sex, n (%) 43 (63.2) 20 (69.0) 23 (85.2) 0.59 0.036 
NYHA class III ot IV, n (%) 15 (22.1) 7 (24.1) 6 (22.2) 0.82 0.99 
Systolic blood pressure, mmHg 113.4 ± 17.2 126.0 ± 20.3 126.8 ± 21.5 0.004 0.004 
Diastolic blood pressure, mmHg 69.3 ± 9.4 76.0 ± 11.5 73.7 ± 9.9 0.006 0.06 
Heartrate, bpm 78.2 ± 13.9 76.1 ± 13.5 70.4 ± 15.6 0.5 0.02 
BMI, kg/m 24.8 ± 4.2 26.1 ± 4.4 25.0 ± 4.2 0.17 0.8 
Previous history of HF 
hospitaliation, n (%) 
41 (60.3) 11 (37.9) 20 (74.1)* 0.043 0.21 
Disease duration,** months 8.6 [3.5, 15.0] 15.4 [5.2, 40.0] 24.4 [6.0, 37.0] 0.021 0.028 
Kidney imvolvement†, n (%) 30 (48.4) 0 1 (3.8) <0.001 <0.001 
eGFR, mL/min/1.73m2 64.6 ± 27.7 73.0 ± 26.9 56.6 ± 17.0* 0.24 0.22 
NT-proBNP, median [IQR] 
3169 
[1321, 12517] 
2093 
 [1111, 3447] 
2365  
[1255, 4175] 0.1 0.28 
   Beta blocker, n (%) 18 (27.7) 11 (39.3) 9 (34.6) 0.27 0.51 
   Ca blocker, n (%) 3 (4.6) 2 (7.1) 0 0.62 0.27 
   Amiodarone, n (%) 2 (3.0) 1 (3.6) 5 (19.2) 0.89 0.008 
   Diuretics, n (%) 38 (57.6) 18 (64.3) 21 (80.8) 0.54 0.037 
   RAS-I, n (%) 12 (18.2) 6 (21.4) 6 (23.1)  0.71 0.59 
Echocardiography      
   LVEDD, cm 4.2 ± 0.5 4.4 ± 0.6 4.3 ± 0.6 0.018 0.2 
   IVS,  cm 1.5 ± 0.2 1.5 ± 0.3 1.7 ± 0.3* 0.9 <0.001 
   PW, cm 1.4 ± 0.2 1.4 ± 0.2 1.6 ± 0.2* 0.35 0.002 
   LV mass/BSA, g/m2  138.5 ± 36.5 148.0 ± 44.8 167.8 ± 46.1 0.28 0.002 
   LVEDV/BSA, ml/m2 44.5 ± 10.7 48.1 ± 11.4 46.1 ± 13.6 0.14 0.55 
   LVESV/BSA, ml/m2 19.1 ± 6.6 21.3 ± 9.4 22.7 ± 8.9 0.19 0.033 
   LV ejection fraction, % 57.5 ± 9.4 56.9 ± 12.6 51.3 ± 11.7 0.79 0.008 
   GLS, % -12.6 ± 4.0 -15.2 ± 4.1 -11.7 ± 3.9* 0.006 0.32 
   E wave,  m/s 0.8  ± 0.2  0.8 ± 0.2 0.7 ± 0.2* 0.74 0.036 
   A wave, m/s 0.6 ± 0.3 0.7 ± 0.3 0.4 ± 0.2* 0.21 0.011 
   E/A 1.8 ± 0.9 1.6 ± 0.9 2.2 ± 1.1* 0.35 0.07 
   E’ (lateral), cm/s 5.9 ± 2.1 6.8 ± 2.9 5.8 ± 1.2 0.13 0.93 
   E/E’ (lateral) 16.3 ± 8.8 14.0 ± 6.4 12.9 ± 4.5 0.24 0.1 
   A’ (lateral), cm/s 6.1 ± 2.9 6.68 ± 3.40 4.1 ± 1.8* 0.45 0.016 
   S’ (lateral), cm/s 6.0 ± 2.2 5.92 ± 2.34 4.7 ± 1.3* 0.91 0.017 
   LA volume/BSA, ml/m2 35.6 ± 12.4 36.7 ± 12.2 44.0 ± 13.9* 0.67 0.006 
   LA width, cm 4.3 ± 0.5 4.2 ± 0.6 4.8 ± 0.5 0.75 <0.001 
Mitral regurgitation, n (%)    0.16 0.16 
   I 26 (38.8) 6 (21.4) 8 (29.6)   
   II 25 (37.3) 9  (32.1) 12 (44.4)   
   III 7 (10.4) 1 (3.6) 5 (18.5)   
   IV 4 (6.0) 0 0   
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Abbreviations: Abbreviations: NYHA, New York Heart Association; eGFR, glomerular filtration 
rate; BMI, body-mass index, LVEDD, left ventricular end-diastolic dimension, IVS, interventricular 
septum; PW,  posterior wall; LVEDV, left ventricular end-diastolic volume, LVESV, left 
ventricular end-systolic volume, BSA, body surface area; GLS, global longitudinal strain; E/A, 
early to late mitral inflow velocity ratio; E’, lateral mitral early relaxation velocity; A’, lateral mitral 
late relaxation velocity; S’, lateral mitral systolic velocity; E/E’, mitral inflow to mitral relaxation 
velocity ratio. 
*Significant (P value<0.05) for AL vs. ATTRwt.  
**Disease duration was calculated as the time interval between the onset of symptoms and the final 
diagnosis of the amyloid disease. The onset of symptoms was derived by patients’ self-report of 
striking changes in their clinical condition in the past weeks/months/years that were judged to be 
compatible with manifestations of the disease.  
†Kidney involvement was defined as the presence of 24-hour urine protein excretion ≥0.5 g/d, and 
renal insufficiency was defined as glomerular filtration rate <60 mL/min.  
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Table 3. LA reservoir, conduit and active function 
A. Patients with cardiac amyloidosis vs. healthy controls.  
  Healthy Controls  CA Unadjusted  
LA function n=20  n=124          P value 
Reservoir function       
   Peak LS, % 40.6 ± 6.2 18.8 ± 11.6 <0.001* 
   Peak LSR, S-1 1.60 ± 0.46 0.84 ± 0.47 <0.001* 
   Total emptying fraction, % 61.0 ± 11.0 45.1 ± 16.7 <0.001* 
Conduit function       
   Early LSR, S-1 -1.38 ± 0.43 -0.71 ± 0.37 <0.001* 
   Passive emptying fraction, % 30.7 ± 11.8 25.7 ± 11.3 0.1 
Active function       
   Late LSR, S-1 -1.48 ± 0.43 -0.84 ± 0.76 0.001* 
   Active emptying fraction, % 42.3 ± 11.6 28.6 ± 16.6 0.001* 
Data are shown as mean ± SD. Abbreviations; LS, longitudinal strain; LSR, longitudinal strain rate. 
*Significant (P value <0.05) after adjustment for LA volume index (LAVI), left ventricular ejection 
fraction and left ventricular end-diastolic pressure (E/E’).  
 
B. Within each etiological subgroup 
  AL ATTRm ATTRwt  Unadjusted  
LA function n=68 n=29 n=27  P value 
Reservoir function       
    Peak LS, % 19.3 ± 11.4 20.1 ± 13.9 16.1 ± 9.1† 0.47 
   Peak LSR, S-1 0.89 ± 0.48 0.88 ± 0.54 0.65 ± 0.29 0.12 
   Total emptying fraction, % 45.9 ± 17.8 45.7 ± 16.8 42.6 ± 14.0 0.73 
Conduit function       
    Early LSR, S-1 -0.71 ± 0.34 -0.81 ± 0.53 -0.59 ± 0.21 0.13 
   Passive emptying fraction, % 25.7 ± 11.7 23.6 ± 11.3 27.8 ± 10.3 0.16 
Active function       
    Late LSR, S-1 -0.88 ± 0.76 -0.95 ± 0.91 -0.61 ± 0.57 0.28 
   Active emptying fraction, % 29.5 ± 17.0 31.8 ± 16.9 22.3 ± 14.1* † 0.16 
Data are shown as mean ± SD. Abbreviations; LS, longitudinal strain; LSR, longitudinal strain rate.  
*Significant (P value<0.05) among groups and †significant (P value<0.05) for ATTRwt vs. AL and 
ATTRm after adjusting for age, sex, body mass index, systolic blood pressure, heart rate, left atrial 
volume indexed to body surface area, severity of mitral regurgitation, left ventricular ejection 
fraction and left ventricular end-diastolic pressure (E/E’).  
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Table 4. Correlation between LA function and age, systolic blood pressure, heart rate, LV function, 
LV structure, and LA size in patients with CA (n=124) 
Variables 
Pearson's Correlation (p value) 
LA reservoir function 
LA conduit 
function 
LA pump 
function 
Peak LS Peak LSR Early LSR Late LSR 
Age -0.25 (p=0.01) -0.32 (p=0.0012) 0.35 (p=0.0003) 0.12 (p=0.24) 
Systolic blood pressure 0.09 (p=0.38) 0.05 (p=0.64) -0.05 (p=0.67) -0.14 (p=0.20) 
Heart rate -0.16 (p=0.10) 0.02 (p=0.86) -0.15 (p=0.12) -0.04 (p=0.74) 
LV structure         
   LVEDV/BSA 0.01 (p=0.92) -0.08 (p=0.42) -0.07 (p=0.50) -0.04 (p=0.67) 
   LV mass index/BSA -0.28 (p<0.0001) -0.26 (p=0.0077) 0.08 (p=0.42) 0.22 (p=0.0270) 
LV function         
   LV GLS -0.60 (p<0.0001) -0.54 (p<0.0001) 0.30 (p=0.0020) 0.54 (p<0.0001) 
   LV ejection fraction 0.48 (p<0.0001) 0.52 (p<0.0001) -0.27 (p=0.0066) -0.41 (p<0.0001) 
   E wave -0.16 (p=0.11) -0.06 (p=0.58) -0.01 (p=0.92) 0.18 (p=0.08) 
   A wave 0.57 (p<0.0001) 0.55 (p<0.0001) -0.34 (p=0.0013) -0.69 (p<0.0001) 
   E/E' (lateral) -0.32 (p=0.0030) -0.25 (p=0.024) 0.20 (p=0.06) 0.26 (p=0.0183) 
LA structure         
   LA width -0.36 (p=0.0002) -0.38 (p=0.0001) 0.41 (p<0.0001) 0.31 (p=0.0017) 
   LA volume index -0.36 (p=0.0002) -0.36 (p=0.0002) 0.30 (p=0.0025) 0.31 (p=0.0021) 
 
Abbreviations: LVEDV, left ventricular end-diastolic volume; BSA, body surface area; GLS, global 
longitudinal strain; E’, lateral mitral early relaxation velocity; A’, lateral mitral late relaxation 
velocity; E/E’, mitral inflow to mitral relaxation velocity ratio. 
  
Page 27 
 
Figure 1A.  
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Figure 2. 
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Supplementary data  
 
Title; Left Atrial Structure and Function in Cardiac Amyloidosis 
 
Authors; Kotaro Nochioka, MD; Candida Cristina Quarta, MD; Brian Claggett PhD;  
Gabriela Querejeta Roca, MD; Claudio Rapezzi, MD; Rodney H. Falk, MD; Scott D. Solomon, MD 
 
 
Supplementary Table 1. Comparison of baseline characteristics between included and excluded 
patients with cardiac amyloidosis 
 
Supplementary Figure 1. Kaplan-Meier Survival Curves for all-cause mortality according to the 
subtype of cardiac amyloidosis. Curves are turnicated at 60 months. 
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Supplementary Table 1. 
 
  
CA patients  
without sinus rhythm 
(Exlcuded) 
CA patients  
with sinus rhythm 
(Included)   
  n=44 n=124    
Age, y 74.1 ± 8.0 64.1 ± 11.9 <0.001 
Male  sex, n (%) 40 (90.9) 86 (69.4) 0.005 
Abnormal rhythm, n (%) 
      AF 26 (59.1)                 ...... 
    AFF 2 (4.5)                 ...... 
    AT 2 (4.5)                 ...... 
    PMI 14 (31.8)                 ...... 
 Etiology, n (%) 
  
<0.001 
   AL 10 (22.7) 68 (54.8)  
    ATTRwt 7 (15.9) 29 (23.4)  
    ATTRm 27 (61.4) 27 (21.8)  
 Disease duration*, median month [IQR]  19.5 [5.0, 33.8] 11.2 [4.2, 28.4] 0.5 
NYHA class III to IV, n (%) 23 (52.3) 28 (22.6) <0.001 
Systolic blood pressure, mmHg 115.8 ± 15.6 119.1 ± 19.8 0.34 
Diastolic blood pressure,  mmHg 69.8 ± 7.8 71.7 ± 10.3 0.29 
Heart rate,  bpm 75.1 ± 14.9 76.0 ± 14.4 0.73 
BMI,  kg/m2 26.5 ± 3.5 25.2 ± 4.3 0.06 
History of HF hospitalization, n (%) 39 (88.6) 72 (58.1) <0.001 
eGFR, mL/min/1.73m2 54.8 ± 20.1 64.6 ± 25.9 0.036 
Median [IQR]NTPro-BNP, pmol/L  3959 [1289, 6658] 2511 [1307, 4925] 0.7 
Medication, n (%) 
      Beta blocker 21 (51.2) 38 (31.9) 0.027 
   Calcium blocker 3 (7.3) 5 (4.2) 0.43 
   Digitalis 3 (7.3) 2 (1.7) 0.07 
   Amirodalone 6 (14.6) 8 (6.7) 0.12 
   Diuretics 39 (95.1) 77 (64.2) <0.001 
   RAS-I 13 (31.7) 24 (20.0) 0.12 
 
 
Abbreviations: AF, atrial fibrillation; AFF, atrial flutter; AT, atrial tachycardia; PMI, pace maker 
implantation; NYHA, New York Heart Association; eGFR, glomerular filtration rate; BMI, body-
mass index; RAS-I, renin angiotensin system inhibitor. *Disease duration was calculated as the time 
interval between the onset of symptoms and the final diagnosis of the amyloid disease. The onset of 
symptoms was derived by patients’ self-report of striking changes in their clinical condition in the 
past weeks/months/years that were judged to be compatible with manifestations of the disease.  
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Supplementary Figure 1. 
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